Literature DB >> 24440159

The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.

Diane M Harper1, Inge Verdenius2, George D Harris3, Angela L Barnett4, Beth E Rosemergey5, Anne M Arey6, Jeffrey Wall7, Gerard J Malnar8.   

Abstract

OBJECTIVE: Economic incentives can positively influence social determinants to improve the health care of the uninsured and underserved populations. The aim of this study was to determine if free HPV4 vaccine would lead to on-time series completion in our safety net health care system in the US Midwest.
METHODS: A nested retrospective cohort study of females receiving HPV4 vaccine between 2006 and 2009 was conducted. Patient characteristics and payor source for each of the three HPV4 doses were abstracted from electronic records. Logistic regression was used to predict on-time completion rates.
RESULTS: The proportion of adolescent and adult females completing three on-time HPV4 doses was equal (21% (28/136) vs. 18% (66/358), respectively) from among the 494 females receiving 927 HPV4 doses in this study. No adolescent receiving free HPV4 vaccine completed three doses. Grant sponsorship of at least one HPV4 dose among adults did not predict three dose on-time completion (OR=1.56, 95%CI: 0.80, 3.06). Neither was adult grant sponsorship of HPV4 significant when analyzing exclusive payor sources vs. a combination of payor sources (OR=0.72, 95%CI: 0.10, 5.17).
CONCLUSIONS: Free HPV4 vaccine does not influence the on-time completion rates among adults.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Compliance; Economic incentive; HPV4 vaccine; Health insurance; Payor source

Mesh:

Substances:

Year:  2014        PMID: 24440159     DOI: 10.1016/j.ypmed.2014.01.007

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  6 in total

1.  A human papillomavirus vaccination program for low-income postpartum women.

Authors:  Abbey B Berenson; Mahbubur Rahman; Jacqueline M Hirth; Richard E Rupp; Kwabena O Sarpong
Journal:  Am J Obstet Gynecol       Date:  2016-02-17       Impact factor: 8.661

2.  Human Papillomavirus (HPV) Health Savings as an Alternative Solution: HPV Vaccination Behavior in Adolescents.

Authors:  Wiwin Lismidiati; Ova Emilia; Widyawati Widyawati
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

3.  Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Authors:  Ting Fan Leung; Anthony Pak-Yin Liu; Fong Seng Lim; Franck Thollot; Helen May Lin Oh; Bee Wah Lee; Lars Rombo; Ngiap Chuan Tan; Roman Rouzier; Damien Friel; Benoit De Muynck; Stéphanie De Simoni; Pemmaraju Suryakiran; Marjan Hezareh; Nicolas Folschweiller; Florence Thomas; Frank Struyf
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.

Authors:  Guodong Liu; Lan Kong; Ping Du
Journal:  Papillomavirus Res       Date:  2016-12

5.  Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students.

Authors:  A Scott LaJoie; Jelani C Kerr; Richard D Clover; Diane M Harper
Journal:  Papillomavirus Res       Date:  2018-03-23

Review 6.  Interventions to increase HPV vaccination coverage: A systematic review.

Authors:  Elizabeth A Smulian; Krista R Mitchell; Shannon Stokley
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.